Hearts & Science expands pharma portfolio with Hyphens Singapore and Allergan Taiwan wins

Omnicom Media Group agency, Hearts & Science, has bolstered its pharmaceutical portfolio after winning the media businesses for Hyphens Pharma in Singapore and Allergan in Taiwan. These wins build on the new business momentum Hearts & Science has experienced in Asia Pacific after winning Warner Bros. Discovery and AS Watson earlier this year.

Hearts & Science is responsible for integrated media planning for Hyphens Pharma Singapore. During the pitch, the agency network demonstrated thought leadership in media investment by aligning strategies with brand objectives, analysing target audience media consumption habits, and leveraging competitive insights.

Hearts & Science’s innovative solutions also enable Hyphens Pharma Singapore to maximise investment efficiency, allowing its brands to adopt a holistic omnichannel approach rather than relying on a single channel. Among the list of products under Hyphens Pharma include Ceradan, D-Vita, Fluanxol, and Rupafin.

In Taiwan, Hearts & Science won the Allergan media business following a competitive pitch. The agency network stood out after successfully developing a strategic theme that positioned Allergan as a leader in aesthetic medicine.

Rochelle Chhaya (pictured), CEO, Hearts & Science APAC, said: “These new business wins deepen our pharmaceutical expertise and reflect the innovative talent that forms a crucial foundation for Hearts & Science. We are constantly seeking new ways to help brands build connections that matter and be where their consumers are. The new partnerships underscore the trust clients place in our capabilities and pave the way for even greater momentum and growth for Hearts & Science in the region.”